FRESENIUS SE+CO.KGAA O.N.
FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
FRE
|
12/8/2023 8:16:05 AM
|
Chg.
-0.080
|
Volume |
Bid9:56:21 PM |
Ask9:56:21 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
28.440EUR
|
-0.28%
|
0
Turnover: 0.000 |
-Bid Size: - |
-Ask Size: - |
16.02 bill.EUR |
3.23% |
11.66 |
Business description
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care.
Management board & Supervisory board
| CEO |
| Michael Sen |
| Management board |
| Sara Hennicken, Dr. Ernst Wastler, Dr. Francesco De Meo, Sebastian Biedenkopf, Pierluigi Antonelli , Helen Giza |
| Supervisory board |
| Wolfgang Kirsch, Prof. Dr. D. Michael Albrecht, Stefanie Balling , Bernd Behlert , Michael Diekmann , Grit Genster , Konrad Kölbl , Frauke Lehmann , Prof. Dr. med. Iris Löw-Friedrich , Oscar Romero de Paco , Susanne Zeidler , Dr. Christoph Zindel |
Company data
| Name: |
Fresenius SE & Co. KGaA |
| Address: |
Else-Kröner-Straße 1,D-61352 Bad Homburg |
| Phone: |
+49-6172-608-0 |
| Fax: |
- |
| E-mail: |
pr-fre@fresenius.com
|
| Internet: |
www.fresenius.de |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Advanced Medical Devices |
| End of financial year: |
12/31 |
| Free Float: |
56.49% |
| IPO date: |
12/18/1986 |
Investor relations
| Name: |
Markus Georgi |
| IR phone: |
+49-6172-608-2485 |
| IR Fax: |
+49-6172-608-2488 |
| IR e-mail: |
ir-fre@fresenius.com
|
Company calendar
|
CW 8 | 2/21/2024
4th Quarter/Annual Report
|
|
CW 19 | 5/8/2024
Interim Report 1st Quarter/3 Months
|
|
CW 20 | 5/17/2024
General Shareholder Meeting
|
|
CW 31 | 7/31/2024
Interim Report 2nd Quarter/6 Months
|
|
CW 45 | 11/6/2024
Interim Report 3rd Quarter/9 Months
|